💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어

Aflibercept

CHEMBL1742982 Phase 4 승인됨 Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A protein that works as a trap to capture vascular endothelial growth factor (VEGF), a substance that stimulates abnormal blood vessel growth in conditions like wet macular degeneration and certain cancers. By blocking VEGF, it helps prevent the leaky, abnormal vessels that can damage vision or feed tumor growth.

치료 영역

Ophthalmology Age-Related Macular Degeneration Oncology

작용 기전

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A protein that works as a trap to capture vascular endothelial growth factor (VEGF), a substance that stimulates abnormal blood vessel growth in conditions like wet macular degeneration and certain cancers. By blocking VEGF, it helps prevent the leaky, abnormal vessels that can damage vision or feed tumor growth.

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Yes, Aflibercept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1742982. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.